SARS-CoV-2 Neutralization Antibody ELISA Kit(Qualitative) (E-EL-E606)

Citations ({{ citationsPage.numTotal }}) Manual MSDS

All	Size	Price	Qty
	96T	$ 576.00

Bulk request >>

Add to cart

For research use only. Order now, ship in 3 days

Product Summary

Sample Volume	50 μL
Total Assay Time	1 h 30 min
Reacitivity	Human
Specificity	This kit recognizes Human SARS-CoV-2 Neutralization Antibody in samples.No significant cross-reactivity or interference between Human SARS-CoV-2 Neutralization Antibody and analogues was observed
Recovery	80%-120%
Sample Type	serum, plasma
Detection Method	Colorimetric method, ELISA, Competitive
Assay Type	Competitive-ELISA
Size	96T
Storage	2-8℃
Expiration Date	12 months

Test Principle

This ELISA kit uses Competitive-ELISA as the method to qualitatively detect the Anti-SARS-CoV-2 Neutralization Antibody in the sample. _x000D_ The micro ELISA plate provided in this kit is pre-coated with recombinant human ACE2. During the reaction, the SARS-CoV-2 Neutralization Antibody in the pretreated samples or controls competes with a fixed amount of human ACE2 on the solid phase supporter for sites on the Horseradish peroxidase (HRP) conjugated recombinant SARS-CoV-2 RBD fragment (HRP-RBD). After 37℃ incubation, the unbound HRP-RBD as well as any HRP-RBD bound to non-Neutralization antibody will be captured on the plate and eventually form the ACE2-RBD-HRP complex, while the circulating neutralization antibodies HRP-RBD complexes remain in the supernatant and are removed during washing. Then a TMB substrate solution is added to each well. The enzyme-substrate reaction is terminated by the addition of stop solution and the color change is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. Compared with the inhibition ratio to judge whether SARS-CoV-2 Neutralization Antibody exists in the tested samples or not.

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originated in Wuhan, China, in December 2019 This virus belongs to the Nidovirales order of the Coronaviridae family, which includes SARS-CoV and MERS-CoV, which caused outbreaks in 2003 and 2012, respectively. SARS-CoV-2 causes coronavirus disease (COVID-19) that can manifest as a severe acute respiratory syndrome. In March 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic. By April 2022, the total disease burden of COVID-19 was more than 500 million people, and over six million fatalities had been recorded worldwide.The serodiagnosis of the SARS-CoV-2 neutralization antibody (NAbs) needs to be explored for an accurate and reliable diagnosis.

Research Area

SARS-CoV-2 , COVID 19

Other Clones

{{antibodyDetailsPage.numTotal}} Results

All

({{item.photos_.length}})

({{item.images_.length}})
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS

Cat.No.：{{item.cat}}

{{index}} {{goods_show_value}}

Other Formats

{{formatDetailsPage.numTotal}} Results

All

({{item.photos_.length}})

({{item.images_.length}})
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS

Cat.No.：{{item.cat}}

{{index}} {{goods_show_value}}

IF：{{item.impact}}

Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}
Reactivity：{{item.species}}

Sample Type：{{item.organization}}

Previous
{{ page }}
Next

Species

{{relatedElisaPage.numTotal}} Results

All

Human

({{item.photos_.length}})

({{item.images_.length}})
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS

Cat.No.：{{item.cat}}

{{index}} {{goods_show_value}}

Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}

Previous
{{ page }}
Next